Work

Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

Year: 2020

Type: article

Abstract: Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.

Source: Breast Cancer Targets and Therapy

DOI: 10.2147/bctt.s224758

Authors: Patrick M Dillon, Christiana M Brenin, Craig L Slingluff Jr

Institution: University of Virginia

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,320